Key Points
- Benjamin Palleiko, KalVista's CEO, sold 3,328 shares on November 12 at an average price of $11.55 for $38,438.40, reducing his stake to 398,981 shares (about a 0.83% decrease); the transaction was disclosed in an SEC filing.
- Shares climbed ~2.4% to $13.40 after the company reported Q3 EPS of ($0.92), topping estimates by $0.04, and revenue of $13.69 million which exceeded expectations.
- Analysts hold a consensus rating of "Moderate Buy" with an average target of $26.63 (ten Buy ratings vs. one Sell), and several institutional investors have recently increased their positions in the stock.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 3,328 shares of the company's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.55, for a total value of $38,438.40. Following the completion of the sale, the chief executive officer owned 398,981 shares of the company's stock, valued at $4,608,230.55. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
KalVista Pharmaceuticals Stock Up 2.4%
Shares of KALV traded up $0.31 during midday trading on Friday, reaching $13.40. 696,356 shares of the stock were exchanged, compared to its average volume of 907,993. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $17.28. The firm has a 50 day simple moving average of $12.22 and a 200-day simple moving average of $12.82. The company has a market cap of $676.96 million, a price-to-earnings ratio of -3.41 and a beta of -0.04.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on KALV shares. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating for the company in a research note on Tuesday. Citigroup reissued a "market outperform" rating on shares of KalVista Pharmaceuticals in a report on Tuesday. JMP Securities lifted their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a "market outperform" rating in a research note on Friday, September 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.63.
View Our Latest Research Report on KalVista Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Invesco Ltd. boosted its position in KalVista Pharmaceuticals by 154.5% during the first quarter. Invesco Ltd. now owns 39,804 shares of the specialty pharmaceutical company's stock valued at $459,000 after purchasing an additional 24,164 shares in the last quarter. Emerald Advisers LLC boosted its stake in KalVista Pharmaceuticals by 15.6% during the 2nd quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company's stock worth $11,735,000 after purchasing an additional 139,859 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its holdings in KalVista Pharmaceuticals by 26.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company's stock valued at $8,693,000 after buying an additional 160,759 shares in the last quarter. Woodline Partners LP grew its holdings in shares of KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after purchasing an additional 329,068 shares during the period. Finally, Wellington Management Group LLP grew its stake in KalVista Pharmaceuticals by 2.8% during the 1st quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company's stock worth $1,457,000 after purchasing an additional 3,405 shares in the last quarter.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
